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Background: Diarrhoea still accounts for considerable mortality and morbidity worldwide. The highest burden is
concentrated in tropical areas where populations lack access to clean water, adequate sanitation and hygiene. In
contrast to acute diarrhoea (<14 days), the spectrum of pathogens that may give rise to persistent diarrhoea
(≥14 days) and persistent abdominal pain is poorly understood. It is conceivable that pathogens causing neglected
tropical diseases play a major role, but few studies investigated this issue. Clinical management and diagnostic
work-up of persistent digestive disorders in the tropics therefore remain inadequate. Hence, important aspects
regarding the pathogenesis, epidemiology, clinical symptomatology and treatment options for patients presenting
with persistent diarrhoea and persistent abdominal pain should be investigated in multi-centric clinical studies.
Methods/Design: This multi-country, prospective, non-experimental case–control study will assess persistent
diarrhoea (≥14 days; in individuals aged ≥1 year) and persistent abdominal pain (≥14 days; in children/adolescents
aged 1–18 years) in up to 2000 symptomatic patients and 2000 matched controls. Subjects from Côte d’Ivoire,
Indonesia, Mali and Nepal will be clinically examined and interviewed using a detailed case report form.
Additionally, each participant will provide a stool sample that will be examined using a suite of diagnostic methods
(i.e., microscopic techniques, rapid diagnostic tests, stool culture and polymerase chain reaction) for the presence of
bacterial and parasitic pathogens. Treatment will be offered to all infected participants and the clinical treatment
response will be recorded. Data obtained will be utilised to develop patient-centred clinical algorithms that will be
validated in primary health care centres in the four study countries in subsequent studies.
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Discussion: Our research will deepen the understanding of the importance of persistent diarrhoea and related
digestive disorders in the tropics. A diversity of intestinal pathogens will be assessed for potential associations with
persistent diarrhoea and persistent abdominal pain. Different diagnostic methods will be compared, clinical
symptoms investigated and diagnosis-treatment algorithms developed for validation in selected primary health care
centres. The findings from this study will improve differential diagnosis and evidence-based clinical management of
digestive syndromes in the tropics.
Trial registration: ClinicalTrials.gov; identifier: NCT02105714.
Keywords: Bacteria, Diagnosis-treatment algorithm, Helminths, Intestinal protozoa, Neglected tropical diseases,
Persistent diarrhoea, Côte d’Ivoire, Indonesia, Mali, NepalBackground
Disease burden due to persistent digestive disorders in
the tropics
Diarrhoeal disorders are among the major communicable
diseases worldwide, with a global burden second only to
lower respiratory infections and greater than the burden
of HIV/AIDS, malaria and tuberculosis [1]. Lack of access
to clean water, improved sanitation and hygiene puts indi-
viduals in resource-constrained settings of tropical and
subtropical countries at high risk of diarrhoea and other
digestive disorders [2–4]. Indeed, severe disease manifes-
tations and associated high mortality occur in children
and immunocompromised individuals, particularly in low-
income countries [5]. Diarrhoea is commonly defined as
three or more loose stools per day and can be classified
according to the total duration of disease (e.g., acute,Fig. 1 Synopsis of important definitions and characteristics of diarrhoeal di
Organization (WHO) and the Infectious Diseases Society of America (IDSA)prolonged, persistent and chronic), the severity (e.g., light,
moderate and severe) and other characteristics (e.g.,
watery, mucous and bloody) [6]. Yet, some of these terms
lack standardisation and are often used interchangeably,
which renders comparison of different studies difficult.
Figure 1 depicts definitions of diarrhoea, based on recom-
mendations put forth by the World Health Organization
(WHO) and expert guidelines [7].
While the epidemiology, aetiological pathogens and
clinical management of acute diarrhoea have been exten-
sively studied in both high-income countries and
resource-constrained settings [8], far less attention has
been addressed to persistent diarrhoea and other non-
acute digestive disorders, such as persistent abdominal
pain [9]. With regard to persistent diarrhoea, for
example, it is conceived that parasitic infections (e.g.,seases, based on recommendations put forth by the World Health
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to be considered. Bacterial and viral infections are
thought to be of lesser importance, although the impli-
cation of bacteria in long-lasting diarrhoea is increas-
ingly being recognised [10]. Current knowledge on
parasitic pathogens giving rise to persistent diarrhoea
mainly stems from experience gained in Western travel
clinics and immunocompromised individuals, while
there is a paucity of data from tropical areas [11, 12].
The few published studies focussed mainly on children,
sample sizes were generally small and only a limited
number of studies had an appropriate design (cohort
studies, case–control studies) to properly investigate the
true relationship between digestive symptoms and infec-
tions caused by specific pathogens [13]. In contrast, acute
diarrhoeal diseases have been studied more intensively all
over the world, and hence the aetiological spectrum is well
characterised [8, 11]. In addition, the recent multi-
country ‘Global Enteric Multicenter Study’ (GEMS)
thoroughly investigated the causes of acute diarrhoea in
infants and young children in developing countries
[14, 15]. As for persistent diarrhoea, the authors of a
systematic review published in 2009 concluded that
further high quality studies are required to elaborate
appropriate clinical guidelines [16]. The review brought to
light that diarrhoeagenic Escherichia coli pathotypes were
found in 30–40 % of children with persistent diarrhoea
and intestinal protozoa in 15–20 % of them. Thus far, the
potential contribution of helminths to this syndrome
has not been studied, although some of these parasitic
worms are classically considered as potential causes
of persistent diarrhoea and persistent abdominal pain
(e.g., Schistosoma mansoni, Strongyloides stercoralis
and Trichuris trichiura) [17].
Neglected tropical diseases and their contribution to
persistent digestive disorders
The neglected tropical diseases (NTDs) comprise an
evolving list of currently over 40 diseases that are caused
by helminths (e.g., Schistosoma), intestinal protozoa (e.g.,
Entamoeba histolytica), bacteria (e.g., Shigella), viruses
(e.g., dengue virus) and fungi (e.g., Paracoccidioides brazi-
liensis) [18]. The global burden of NTDs accumulates to
approximately 48 million disability-adjusted life years
(DALYs) [19]. NTDs are closely linked to conditions of
poverty which hinder social and economic development in
endemic countries and negatively impact on people’s qual-
ity of life and wellbeing at many levels [20–22].
It is poorly understood to what extent NTDs may con-
tribute to the clinical syndrome of persistent diarrhoea and
persistent abdominal pain in resource-constrained settings.
Long-lasting gastrointestinal complaints are a major reason
for consultation of health centres or hospitals in the tropics,
but few guidelines exist regarding appropriate clinicalmanagement. The problem is exacerbated by a lack of
adequate diagnostic tools to guide treatment and control
[23, 24]. If diagnostic techniques are available at all in low-
income countries, they are usually not sensitive enough to
detect NTDs with adequate accuracy (e.g., employment of
unstained direct faecal smears for the microscopic diagnosis
of intestinal parasites). Additionally, individuals with per-
sistent digestive disorders are commonly managed as out-
patients in underfinanced primary health care centres in
rural areas, where health system resources are even weaker
than in hospital settings [25–28]. Due to the lack of ad-
equate diagnostics and the uncertain role NTDs play as
causative agents of persistent digestive disorders, clinicians
may frequently assume a bacterial infection and prescribe
antibiotic treatment without detailed diagnostic work-up. If
symptoms persist or deteriorate despite anti-infective ther-
apy, empirical treatment with one or several antiparasitic
drugs may be added. However, it is unknown whether such
an approach is medically appropriate, whether adequate
clinical cure rates can be achieved and whether this strategy
is cost-effective [29].
NIDIAG: developing diagnosis-treatment algorithms for
neglected clinical syndromes
NIDIAG is an international collaborative research
consortium that aims at improved clinical manage-
ment of common clinical syndromes in the tropics
(http://www.nidiag.org). This 5-year project is funded
by the European Commission (EC), Framework Programme
7. NIDIAG aims to develop improved, patient-centred ap-
proaches to be applied in primary health care centres of
resource-constrained settings. Three clinical syndromes
are being investigated: (i) persistent digestive disorders
[9]; (ii) persistent fever [30, 31]; and (iii) neurological
disorders [32]. Particular emphasis is placed on the
contribution of NTDs to each syndrome.
The current study protocol focuses on persistent digest-
ive disorders, which are defined as diarrhoea (≥14 days) in
individuals aged ≥1 year and/or abdominal pain (≥14 days)
in children and adolescents aged 1–18 years. Adults pre-
senting only with abdominal pain will not be studied be-
cause a considerable proportion of persistent digestive
symptoms is due to non-infectious causes and beyond the
scope of this study [33]. However, children presenting
with persistent abdominal pain will be included, even in
the absence of diarrhoea. Indeed, it is commonly assumed
among tropical clinicians that long-lasting abdominal pain
is associated with parasitic and other intestinal infections
in this age group, but further clinical evidence is war-
ranted [34].
Goal, aims and objectives
The overarching goal of this study is to develop clinical
algorithms that provide an evidence-based syndromic
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shall lead to better diagnosis and management of patients
with persistent digestive disorders in resource-constrained
settings. To this end, we will pursue a multi-centric, pro-
spective case–control study in Côte d’Ivoire, Indonesia,
Mali and Nepal. Patients (≥1 year old) presenting with
persistent diarrhoea (≥14 days) and/or children and ado-
lescents (aged 1–18 years) with persistent abdominal pain
(≥14 days) will be enrolled. Insights gained during the
study will help to develop and, in a second study phase, to
validate readily applicable diagnostic algorithms that shall
facilitate the clinical decision-making and management of
patients presenting with persistent diarrhoea and abdom-
inal pain. The following aims and specific objectives are
related to this goal.
Aims
1. To improve the quality of clinical care for persistent
diarrhoea and persistent abdominal pain through the
development of evidence-based diagnosis-treatment
algorithms for use in primary health care centres.
2. To identify the major NTDs and other infectious
agents (i.e., bacteria and parasites) that give rise to
persistent digestive disorders and to assess their
relative contribution to this clinical syndrome.
3. To compare different diagnostic methods and to
assess their diagnostic accuracy, including clinical
features, conventional laboratory techniques, rapid
diagnostic tests (RDTs) and molecular assays for the
diagnosis of selected pathogens.
4. To assess the clinical response to commonly
employed empirical treatment options for persistent
digestive disorders.
Specific objectives and activities
1. To examine stool samples from symptomatic patients
presenting with persistent diarrhoea and children/
adolescents with persistent abdominal pain with a range
of standardised, quality-controlled laboratory techniques
(e.g., microscopic techniques, RDTs and stool culture)
for detection of parasites and pathogenic bacteria.
2. To examine stool samples from matched healthy
controls without gastrointestinal complaints with
the same suite of diagnostic tests and approaches.
3. To retrospectively analyse a (sub-)sample of stool
specimens using multiplex polymerase chain reaction
(PCR) assays in reference laboratories. PCR tests will be
used to assess the diagnostic accuracy of conventional
tests, as well as to obtain data on additional pathogens.
4. To assess the relative importance of the pathogens
detected in symptomatic individuals, as compared to
healthy controls.5. To perform a standardised medical examination on all
participants and to accurately document clinical signs
and symptoms, risk factors, clinical management and
response to treatment in a case report form (CRF).
6. To calculate the predictive values of clinical and
laboratory data to provide evidence-based data for
the development of a diagnostic algorithm.
7. To develop and validate one or several diagnosis-
treatment algorithms for the management of
persistent digestive disorders in primary health care
settings of resource-limited countries.
8. To assess the cost-effectiveness of different
approaches for the diagnosis of selected NTDs in pa-
tients presenting with persistent digestive disorders.
Methods/Design
Study area
For this study, four low- or middle-income countries, two
in West Africa (Côte d’Ivoire and Mali) and two in Asia
(Indonesia and Nepal), were selected as study sites to
cover a broad geographic range, diverse pathogen profiles
and different health systems. Prior to the selection of the
study sites, an extensive review of existing epidemiological
data on diarrhoeal diseases and the targeted NTDs in the
study countries was conducted. An assessment of cur-
rently employed diagnosis-treatment practices and on-
going control activities in each country confirmed that all
four countries are endemic for the main target NTDs/
pathogens under investigation. In Côte d’Ivoire and Mali,
currently no national guidelines or algorithms exist for the
diagnosis and treatment of persistent diarrhoea or persist-
ent abdominal pain. In Nepal, some paediatric guidelines
exist, but no standardised approach towards persistent
diarrhoea in adults has been developed thus far. Indonesia
is the only country where, since 2011, a national
programme for the management of diarrhoeal diseases is
in place. All study countries have national programmes for
control of NTDs, but there is considerable variation with
regard to control approaches and the spectrum of NTDs
covered, varying from strategies that target exclusively in-
testinal helminths (e.g., in Nepal) to multidimensional in-
tegrated NTD control programmes (e.g., in Mali) [35].
Our research will be conducted in peripheral health
centres and referral level hospitals in order to capture a
large variety of clinical presentations of the digestive
syndrome. The study sites were selected on the basis of
the following criteria: (i) location in remote rural areas
or deprived urban settings; (ii) existing referral links be-
tween primary health care centre and district hospital
(e.g., for diagnosis and treatment of complicated or se-
vere conditions); (iii) adequate patient care in the refer-
ral hospitals; (iv) persistent digestive disorders being a
relevant and frequently occurring clinical syndrome, as
judged by the local physicians and nurses; (v) available
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standard first-line tests and to process field samples for
external work-up; and (vi) key staff trained in good clin-
ical practice (GCP) and good clinical laboratory practice
(GCLP).
Country-specific assessments were carried out during
the site selection procedure. The following seven study
centres were selected in the four study countries (Fig. 2):
 Côte d’Ivoire
– Hôpital Méthodiste de Dabou, a regional reference
hospital based in Dabou, approximately 30 km
west of Abidjan, the country’s economic capital.
 Indonesia
– Tulehu Hospital, based in Tulehu in Maluku
province, approximately 100 km northeast of
Ambon City, the province’s capital; and
– Tulehu Health Centre, also situated in Maluku
province in close proximity (approximately 1 km)
to the Tulehu Hospital.
 Mali
– Niono District Reference Health Centre, based in
Niono, approximately 300 km northeast of the
country’s capital Bamako; and
– Institut National de Recherche en Santé Publique
(INRSP) in Bamako.
 Nepal
– B P Koirala Institute of Health Sciences, situated
in Dharan, approximately 350 km southeast of
the country’s capital Kathmandu; andFig. 2 World map and country-specific maps of Côte d’Ivoire, Indonesia, Mali and
study on persistent digestive disorders– Dhankuta District Hospital in Dhankuta,
approximately 50 km north of Dharan.Study design
Our investigation is designed as a prospective, non-
experimental case–control study to determine the rela-
tive importance of NTDs in patients who present with
persistent digestive disorders. The case–control design
was adopted because of the observation that multiple di-
gestive pathogens may be found even in asymptomatic
individuals, and hence these may rather represent ‘inno-
cent bystanders’ that do not play a causal role in the
aetiology of the persistent symptomatology [36, 37]. We
believe that the inclusion of a control group will provide
discriminative data on the distribution of pathogens and
might be useful to enhance interpretation of causal asso-
ciations [38, 39].
Study participants
The inclusion criteria for cases are (i) all individuals (aged
≥1 year) presenting with persistent diarrhoea (≥14 days);
and/or (ii) children/adolescents (aged 1–18 years) with
persistent abdominal pain (≥14 days). For persistent diar-
rhoea, the WHO definitions are used (see also Fig. 1).
WHO defines diarrhoea as the passing of three or more
loose stools within 24 h. A new episode of diarrhoea can
occur after two full days without diarrhoea. Episodes of
diarrhoea lasting for 14 days and longer are defined as
persistent [6]. For persistent abdominal pain, no offi-
cial WHO definition exists. Here, we define persistentNepal, indicating the sites of patient recruitment for the NIDIAG
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lasting for at least 14 days (possibly with intermittence/
recurrence). To each enrolled patient, one control without
any gastrointestinal complaints will be matched by age
group, sex and geographical location of residence. These
may be patients who present to the same hospital or out-
patient facility as the case, but with non-related complaints
(e.g., with ophthalmological diseases or consulting for vac-
cination or ‘routine’ check-up). If the patient was referred
to the hospital by one of the peripheral health facilities in
the catchment area, the control will be (actively) selected
through the same or a nearby peripheral health facility.
Patients and controls presenting with the following
characteristics will be excluded: (i) unwilling or unable
to give informed consent; (ii) unable in the study physi-
cian’s opinion to comply with the study requirements;
(iii) presenting with clinical jaundice (as assessed by dir-
ect observation of the conjunctivae); (iv) already partici-
pating in other ongoing diagnostic studies and/or
clinical trials; and (v) in need of immediate intensive or
surgical care (including severely malnourished children).
Sample size
The lack of available data on the frequency of persistent
digestive disorders in resource-constrained settings and
the diversity of implicated infectious pathogens renders
sample size calculations difficult [40]. A systematic re-
view on pathogens associated with persistent diarrhoea
in children in low- and middle-income countries re-
ported prevalences of about 10 % for Giardia intestina-
lis, 5–10 % for Campylobacter spp. and around 5 % for
Cryptosporidium spp. [16]. Prior data from Côte d’Ivoire
[37, 41] indicate that the probability of infection with
target pathogens such as S. stercoralis is around 10-15 %
in symptomatic cases and 5–10 % in healthy controls. If
the true probability of infection among cases is 10 %,
435 cases and 435 controls need to be included to be
able to reject the null hypothesis that the infection rates
for case and controls are identical with a probability
(power) of 0.8 (2-sided alpha = 0.05). To compensate for
loss to follow-up of 10 %, we aim at enrolling a total of
500 cases and 500 controls in each of the four study
countries. It should be noted, however, that no robust
information exist to date, and hence most data and
resulting calculations remain somewhat speculative. As
most reported prevalences of several important target
NTDs (e.g., hookworm and G. intestinalis) are in the
same range as described above, we adhered to these as-
sumptions, and hence, we aim for a total of 2000 pa-
tients and 2000 matched controls.
Patient recruitment and clinical management
The recruitment strategy will be adapted to the local set-
ting, taking into consideration the local norms, cultureand health care system organisation. Before the start of
the study, appropriate context-adapted mechanisms will
be set up to inform the community’s representatives in
the catchment area of the respective study centres about
the study, its objectives, the implications for the commu-
nity and potential future impacts. All procedures during
the study will be guided by an extensive set of spe-
cifically developed standardised operating procedures
(SOPs). Figure 3 shows the patient recruitment and
study flow according to the respective SOPs. Whenever
a patient presents to one of the study centres with self-
reported persistent digestive disorders (≥14 days), the
care provider will immediately contact the study investi-
gator. The study investigator will assess inclusion/exclu-
sion criteria by medical history taking, review of existing
medical documents (e.g., results of laboratory tests, note
from referring physician) and a rapid clinical assessment.
Patients who meet the inclusion criteria will be invited
to participate in the trial. Once informed consent has
been obtained, the selected individuals will undergo a
full clinical assessment and will be asked to provide one
fresh stool sample. In the two West African countries,
an additional urine sample will be obtained for diagnos-
tic work-up. Based on the initial assessment, the study
physician will document a syndromic diagnosis (e.g., sus-
pected parasitic intestinal infection) as well as any thera-
peutic decision (e.g., initiation of empirical treatment).
Of note, all decisions will be documented, but the
current practices of the clinician will not be influenced
(non-interventional trial). All patients will be followed
and a systematic second visit for in-depth evaluation will
be conducted 3–5 days after the first visit. By the time of
the second visit, all microbiological laboratory results
will be available and the treatment may be adapted in
case of a specific detected pathogen or an unsatisfactory
clinical evolution. Patients with persistent symptoms will
be asked to provide another stool sample for detailed
diagnostic work-up. If need be, a patient might be
assessed during a third visit that is performed one to
two weeks after the second visit. In case of clinical com-
plaints being still present, a third stool sample may be
tested and treatment might be modified again. Add-
itional visits and further laboratory work-up will be left
to the discretion of the care provider. Each time, new or
persistent clinical symptoms and signs as well as all
treatment decisions will be recorded. The final diagnosis
for each patient will be based on the combination of la-
boratory tests, clinical response to treatment and add-
itional investigations requested by the treating clinician
(e.g., abdominal ultrasound examination).
Individuals without any gastrointestinal complaints will
be invited to participate as controls in this trial. After in-
formed consent has been obtained, the diagnostic proce-
dures applied to the controls are identical as for the cases.
Fig. 3 Patient flow of the NIDIAG study on persistent digestive disorders, as outlined in a specific standardised operating procedure (SOP)
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All laboratory activities will be carried out according to
the specific SOPs. The diagnostic tests to be employed
were selected after a systematic review of the peer-
reviewed literature and standard textbooks, supple-
mented with expert opinion [9]. Four different classes of
tests will be employed during the study, namely (i) stool
microscopy and stool concentration techniques for the
diagnosis of intestinal protozoa and helminths (on site;
all study countries); (ii) a stool-based RDT for the diag-
nosis of Cryptosporidium spp. and G. intestinalis (on
site; all study countries) and a urine-based RDT for the
detection of S. mansoni (on site; only in Côte d’Ivoire
and Mali); (iii) bacteriological stool culture for the diag-
nosis of selected enteric bacteria in patients presenting
with persistent diarrhoea (in national reference labora-
tories; all study countries except Indonesia, where thecapacity and available laboratory equipment to perform
bacteriological stool cultures in the selected centre did
not meet the required reference standards); and (iv) PCR
assays for the detection of parasitic and, possibly, add-
itional bacterial and viral pathogens (in European refer-
ence laboratories; ethanol-fixed stool samples from all
study countries). Table 1 provides an overview of the ap-
plied tests and the pathogens that can be detected by the
individual techniques. Most of the test results will be
available within 3 days after provision of the stool sample
so that targeted treatment of the detected pathogen can be
offered to the patient, based on national guidelines and
evidence-based treatment recommendations. However, it
is important to note that the PCR tests will only be con-
ducted several weeks or months after stool sampling, and
hence, these test results will not be available in a timely
manner to guide clinical patient management.
Table 1 Diagnostic tests to be employed on stool (and urine) samples from patients with persistent digestive disorders and healthy
controls in Côte d’Ivoire, Indonesia, Mali and Nepal during the NIDIAG study. Note: except for the rapid diagnostic test (RDT) for
Schistosoma mansoni which uses urine, all tests are performed on stool samples
Diagnostic test Targeted pathogens Reference(s)
Microscopy
Direct faecal smear Helminths, intestinal protozoa [55]
Kato-Katz thick smear Helminths [56]
Acid-fast staining Cryptosporidium spp., Cyclospora cayetanensis,
Cystoisospora belli
[57]
Baermann funnel concentration technique Strongyloides stercoralis, hookworm [41, 58]
Formalin-ether concentration technique Helminths, intestinal protozoa [59, 60]
Mini-FLOTAC Helminths [61, 62, 63]
Culture
Bacteriological stool culture Salmonella spp., Shigella spp., Campylobacter spp.,
Yersinia spp.
[9]
Koga agar culture Strongyloides stercoralis, hookworm [64–67]
Rapid diagnostic tests (RDTs)
Crypto/Giardia DuoStrip Cryptosporidium spp., Giardia intestinalis [37]
Circulating cathodic antigen (CCA)a Schistosoma mansoni [68–72]
Molecular post-hoc testing on ethanol-fixed
stool samples
Multiplex PCR Helminths, intestinal protozoa (all samples);
diarrhoeagenic bacteria and viruses
(selected sub-sample)
[73–76]
aThis test will only be employed in Côte d’Ivoire and Mali, because S. mansoni does not occur in Indonesia and Nepal
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We will adhere to rigorous quality control procedures
for all laboratory investigations specified in Table 1. A
‘quality manager’ will be designated in each study site to
actively monitor the laboratory activities throughout the
study. This person will verify the storage conditions and
accountability of the reagents used for the studies. It will
be carefully checked that samples are collected, trans-
ferred, processed, analysed and stored according to
SOPs. Moreover, 5–10 % of all processed stool samples
will be re-read under a microscope by experienced la-
boratory technicians. A photo of each RDT result will be
taken at the time of reading, and subsequently docu-
mented. The photos and the recorded results will be
checked for consistency by the quality manager. Add-
itionally, external monitoring will be conducted at regu-
lar intervals, and according to GCLP standards. These
measures will ensure quality and reproducibility of all la-
boratory results within and across study countries.
Economic evaluation
The cost and cost-effectiveness of the different diagnos-
tic laboratory tests and diagnosis-treatment algorithms
will be assessed and compared to existing practice. The
economic evaluation will take the perspective of the
public health care system, focussing on practice andimplementation at the primary care level. The costing of
the baseline and the diagnosis-treatment algorithm, in-
cluding all diagnostic tests used in the study, will be
done using a combination of top-down and bottom-up
costing methodologies [42]. Information will be collected
on recurrent items (e.g., staff, supplies and reagents) and
capital costs (e.g., building, equipment and furniture).
For the estimation of the unit costs of diagnostic tests,
information on resource usage will be collected through
time-and-motion studies. Resources will be valued at
their opportunity cost, including the value of donated or
subsidised items (i.e., economic costing). Capital items
will be annualised over their expected life span.
Data collection
All clinical and laboratory data will be recorded in a spe-
cifically designed and pre-tested CRF. Two distinct CRFs
were developed; one for patients and one for controls.
The study investigator/clinician will complete one CRF
for each study participant to document demographic
data (e.g., age, sex and residency), clinical data (e.g.,
medical history, including data on previous exposure
and risk behaviour, current symptoms, physical examin-
ation, new or persistent clinical symptoms and signs,
clinical evolution, final clinical outcome), laboratory data
(e.g., clinical sampling, test results for each sample,
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sis, working and final diagnosis based on available clin-
ical and laboratory results) and treatment decisions (e.g.,
abstention or initiation of empirical or targeted treat-
ment, additional treatments, treatment modifications
and treatment response). All treatments are recorded in
a separate document (medication form). Any additional
clinical or laboratory investigations as well as unsched-
uled visits will be documented. The consistency and
quality of data collection will be checked regularly by an
internal quality control manager and during the recruit-
ment phase via external monitor visits.
Data management and storage of data
Data management at the respective study centres will be
carried out under the guidance and supervision of a cen-
tral data manager. The local data manager will be re-
sponsible for supervising data entry and local data
management. Completed CRFs will be submitted to the
local data management, where data of the CRF will be
recorded into the study database. After data cleaning
and database lock, the database will be shared with the
collaborating institutes. All data entry and management
will be done by trained study personnel. As required by
international guidelines and national regulations, the
study file, signed informed consent sheets, source docu-
ments, copy of the CRF and subject identification codes
will be retained for at least 2 years (or for the time
period required by national legislation) at each study site
(ICH-GCP 4.9.5) to allow for audits and inspections
even after the study completion. The study investigators
are responsible for reporting a patient’s and control’s per-
sonal details and identification number in a participant
identification list. To ensure confidentiality, this list will be
kept in a separate, locked cupboard together with the
signed informed consent forms and only the study investi-
gators and clinical study staff will have access to it.
All laboratory specimens, including preserved samples,
and all subject-related reports, forms and study data will
be identified by a coded number. Subject names will not
be used. All local databases will be secured with
password-protected access systems. A list of authorised
personnel to access the databases throughout the study
will be held. Regular backups of the database at the
study sites will be performed and shared with the central
data manager. Computers and other study hardware
(e.g., external memory to store backups) will be used
only for study purposes and kept in locked cupboards
and/or rooms. Any personal study information will not
be released to anybody outside the medical team, except
to competent authorities for independent monitoring,
auditing and inspection. Throughout the study, strict
confidentiality, quality, and security of the subjects’ data
will be pursued.Data analysis
Statistical analyses will be carried out with STATA ver-
sion 12 (StataCorp LP; College Station, USA) or SPSS
Statistics version 22 (IBM Corporation; Armonk, USA).
The prevalence and, in case of parasitic infections, the
intensity of infection with targeted NTDs will be utilised
as primary outcome measure. Logistic regression models
will be employed to estimate associations of putative
pathogens with persistent digestive disorders. The aetio-
logical fraction for matched case–control studies will be
calculated to estimate the fraction of cases with digestive
disorders due to a specific pathogen. The sensitivity of
clinical and laboratory predictors and of RDTs will be
calculated as the proportion of patients with a given dis-
ease (“confirmed” diagnosis only) who present with a
clinical feature or show a positive test result. The specifi-
city of clinical and laboratory predictors and of RDTs
will be calculated as the proportion of individuals with-
out the disease (“confirmed” diagnosis only) who do not
present with this feature or show a negative test result.
Positive and negative likelihood ratio of clinical and la-
boratory predictors and of RDTs will be calculated using
standard formulas. The positive likelihood ratio (LR+)
will be obtained by dividing the sensitivity of individual
predictor by 1 minus the specificity of the predictor. The
negative likelihood ratio (LR-) will be obtained by divid-
ing 1 minus the sensitivity of the predictor by its specifi-
city. The positive predictive value (PPV) of clinical and
laboratory predictors and of RDTs as well as their com-
bination will be calculated according to Bayes’ formula
as the proportion of patients with a clinical feature or a
positive test result who have the disease. The negative
predictive value (NPV) of clinical and laboratory predic-
tors and of RDTs as well as their combination will be
calculated as the proportion of individuals without this
feature or with a negative test result who do not have
the disease.
Ethical approval
The study protocol was discussed, reviewed and modi-
fied by several experts within the NIDIAG research con-
sortium and its independent scientific and ethical board.
It was approved by the institutional review boards (IRBs)
at the Institute of Tropical Medicine (ITM) in Antwerp,
Belgium and the Swiss Tropical and Public Health Insti-
tute (Swiss TPH) in Basel, Switzerland prior to external
review. Country-specific approvals were subsequently
granted by the followings ethics committees: (i) Univer-
sity of Antwerp in Belgium (12 August 2013); (ii) Gadjah
Mada University in Indonesia (21 November 2013); (iii)
‘Ethikkommission beider Basel’ (EKBB) in Switzerland
(22 November 2013); (iv) ‘Institut National de Recherche
en Santé Publique’ in Mali (28 November 2013); (v)
Ministry of Health in Côte d’Ivoire (28 November 2013);
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Nepal (29 January 2014). The trial is registered on Clini-
calTrials.gov (identifier: NCT02105714). Should any eth-
ical issues arise during the conduct of the study, these
will be promptly discussed within the NIDIAG ethical
board and referred to the concerned IRBs.
Policy and dissemination strategy
NIDIAG aims to improve quality of clinical care for
three common syndromes in the tropics and will provide
specific efforts to translate evidence into policy. Hence,
policy makers will be involved in the project from an
early stage and will be consulted during the development
of the following decision support tools: (i) development
and validation of algorithms for the clinical management
of persistent digestive disorders; (ii) cost estimates and
cost-effectiveness analyses of integrated algorithms and
diagnostic platforms compared to single-disease oriented
laboratory tests; and (iii) analysis of acceptability and ap-
propriateness of innovative diagnosis-treatment tools for
application in the primary health care settings. A com-
prehensive translation-to-policy strategy will be put in
place and insights gained through the NIDIAG study
will be widely disseminated among patient groups and
participating communities.
Discussion
Digestive disorders are among the major clinical syn-
dromes that characterise a host of NTDs in Africa, Asia,
Latin America and elsewhere. The morbidity due to
diarrhoeal diseases in low- and middle-income countries
continues to be considerable. While the aetiological
spectrum of acute diarrhoea has been widely investi-
gated, the major pathogens giving rise to persistent diar-
rhoea and other non-acute digestive disorders remain to
be elucidated [9, 16].
There is a pressing need to assess frequently encoun-
tered clinical syndromes in resource-constrained settings
from a patient-centred perspective, rather than relying
on single disease-oriented approaches. Indeed, a recent
study in Tanzania investigated the causes of fever in chil-
dren and brought to light that viral infections predomin-
ate and are considerably more common than parasitic
diseases (e.g., malaria) and bacterial infections (e.g., bac-
terial pneumonia) [43]. In contrast to this finding, clini-
cians commonly prescribe antimalarial and antibacterial
medication in the absence of diagnostic testing facilities,
which in turn leads to overtreatment with potential
negative consequences (e.g., development of resistance
and drug toxicity). It is conceivable that similar miscon-
ceptions and mismanagement apply to other clinical
syndromes, including persistent diarrhoea and persistent
abdominal pain, which is the focus of the current study
protocol. It has been postulated that an improvedsyndromic approach to highly prevalent complaints such
as persistent diarrhoea, persistent abdominal pain or
long-lasting fever will require (i) a deeper understanding
of the aetiology and epidemiology of the target diseases;
(ii) the availability of readily applicable RDTs in the most
affected areas; and (iii) the development of evidence-
based algorithms for the management of these syn-
dromes [30]. NIDIAG aims to address these issues for
three clinical syndromes: the persistent digestive disor-
ders discussed here, along with neurological disorders
and persistent fever.
Several considerations underscore the need for a con-
certed, multi-centric assessment of persistent diarrhoea
and persistent abdominal pain in resource-constrained
settings, with particular emphasis on the primary health
care level. First, digestive syndromes are associated with
many different NTDs, particularly helminth and intes-
tinal protozoa infections [44], but the magnitude of their
contribution to persistent digestive disorders is largely
unknown. A single disease perspective will not be able
to determine the relative importance of NTDs in pa-
tients who present with persistent diarrhoea and persist-
ent abdominal pain; hence a syndromic and patient-
centred approach seems more promising. Second, for
some of the NTDs that may give rise to digestive disor-
ders, public health programmes to control these infec-
tions have been implemented [45]. For instance, the
control of several helminth NTDs currently relies on
preventive chemotherapy; that is the regular, large-scale
administration of one or several orally available drugs
with the aim of reducing the parasite load and thus pre-
venting the development of severe disease [46, 47]. These
strategies offer opportunities for a rapid impact at low
cost in resource-constrained settings, especially in areas
where the targeted diseases are highly prevalent. How-
ever, the long-term sustainability of these programmes
has been questioned [48, 49]. Recently, public health
specialists put particular emphasis on integrated control
approaches that go beyond preventive chemotherapy
[50, 51]. The disease-specific focus of many NTD control
programmes has led to fragmentation and gaps in patient
management. At the primary health care level, however,
nurses and physicians do not deal with a single disease,
but with patients presenting with a wide spectrum of com-
plaints. Among these clinical syndromes, they have to rec-
ognise the specific NTDs and discriminate these from a
constellation of other illnesses. Hence, there is a need for
evidence-based guidelines on the management of a spe-
cific clinical syndrome and the contribution of NTDs
rather than single programmes targeting one of the
aetiological agents. There is growing consensus that well-
functioning health systems are required to achieve sustain-
able NTD control and improved diagnosis-treatment
algorithms are key to this [52, 53]. Third, as control of
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settings, it will be important to conduct studies in the pri-
mary health care settings to allow for an unbiased detec-
tion and surveillance of these infections. Such an
assessment can only be achieved on a large scale by the
first-line caregivers and available evidence-based algo-
rithms for diagnostic work-up would provide a useful tool
for patient management.
Taken together, the NIDIAG digestive study offers an
integrated syndromic approach to NTD-related clinical
syndromes, focussing on digestive disorders defined as
persistent diarrhoea (≥14 days of diarrhoea in all individ-
uals aged ≥1 year) and persistent abdominal pain
(≥14 days in children and adolescents aged 1–18 years).
The overarching goal is the elaboration of evidence-
based diagnosis-treatment algorithms centred on pa-
tients in resource-constrained settings, where available
data are scant and patient management is often driven
by ‘empirical evidence’ and local beliefs. Furthermore,
this study will help to assess the contribution of NTDs to
persistent digestive disorders and, subsequently, develop
and evaluate sustainable and cost-effective control pro-
grammes for these infections. Additionally, the NIDIAG
digestive study will optimise the use of existing diag-
nostic tests and advance the development of new
methods, which must be simple to use, affordable for
application in low-income countries and able to de-
tect a broad spectrum of intestinal pathogens with
high accuracy [54]. Finally, the insights gained during
this multi-country prospective study will also help to
re-estimate the burden of persistent digestive disor-
ders and may influence future public health recom-
mendations and health policy planning.
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